FDA rejects Takeda/Shire candidate

Another clinical trial of TAK-721 is needed, says the US Food and Drug Administration, which has rejected the drug.

A new potential treatment for eosinophilic esophagitis (EoE), chronic inflammation of the esophagus, has been shot down by the FDA.

The agency sent a complete response letter to Takeda, which developed the candidate, after reviewing the marketing authorization application and accompanying data.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs